Project cooperationUpdated on 19 January 2026
Organ on chips, organoids and other NAMs for biomedical research
Business Development Manager, PharmD, MPH at LEITAT
Barcelona, Spain
About
-
Organ-on-chip contribution:
• Design, prototype ad upscale microfluidics/organ-on-chip devices using tailored matrices and hydrogels, cell types, and configurable architectures that support organ-level development and function.
• Adding gravitational and pressurized perfusion systems to create different levels of complexity.
• Sensing integration, detection of surveillance, anticipation of events, correction of processes in culture, can be added to improve the design.
• Our platforms enable the generation of both healthy and pathological models to evaluate drug safety and efficacy across multiple organs and diseases. We have colorectal cancer model, liver, lung and gut, but are open to consider development of different organs /indications.
• The models can be more personalized with cell monitoring, viability and cytotoxicity assessment, TEER permeability. They can also be coupled with advanced detection of cell markers, ECM components, ions, pH, metabolites, and cytokines.
• Finally, we can create digital-twin technologies of the organ on chip system
• We can use robotics to automate the platform and manipulate the hydrogels. This way we can think about a standardised platform more aligned with future regulations.
-
Organoids and 2D models:
We can also develop various in vitro models from iPSCs, such as:
• 3D organoid cultures (we can also consider other indications): Corneal, Intestinal, Brain, Pancreatic, Lung
• 2D cultures (since we can differentiate iPSCs into the three germ layers, we could also consider differentiating them into other relevant cell types): Motor neurons, Cardiomyocytes, Hepatocytes, Pancreatic cells -
Bioreactors and biosensors for in vitro models
-
Bioprinted tissue constructs
-
Virtual Twins
-
Advanced in vitro model muscle contraction (patented technology)
Topic
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Organisation
Similar opportunities
Project cooperation
Patient-Derived iPSC & 3D Human Tissue NAM Platforms
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Sofia Aires Martins
Research Manager at Institute for Bioengineering and Biosciences
Lisboa, Portugal
Project cooperation
NAM: organoids and OoC for drug discovery, and precision medicine applications
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Una Riekstina
full professor at Department of Pharmaceutical Sciences, University of Latvia
Riga, Latvia
Project cooperation
Digital Twin–Guided Development of Stem Cell Organoids for Disease Modeling and Tissue Repair
- Consortium/Coordinator seeks Partners
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Ahmed Morsy
Assistant Professor at Konkuk university
Seoul, South Korea